TY - JOUR
T1 - Risk of over- And under- treatment with levothyroxine in primary care in Copenhagen, Denmark
AU - La Cour, Jeppe Lerche
AU - Medici, Bjarke Røssner
AU - Grand, Mia Klinten
AU - Nicolaisdottir, Dagny Ros
AU - Lind, Bent
AU - Faber, Jens
AU - Andersen, Christen Lykkegaard
AU - Nygaard, Birte
N1 - Publisher Copyright:
© 2021 BioScientifica Ltd.. All rights reserved.
PY - 2021/10/11
Y1 - 2021/10/11
N2 - Objective: A decrease over time in thyroid stimulating hormone (TSH) levels when initiating levothyroxine (L-T4) therapy for hypothyroidism has been reported, where treatment most often is initiated with TSH levels below 10 mIU/L. The primary objective of this study was to investigate whether this lower TSH threshold resulted in an increased number of overtreated patients.Design and method: Retrospective cohort study comprising inhabitants in Copenhagen had TSH measurements requested by general practitioners which led to a new prescription of L-T4 between 2001 and 2012. Over- and under- treatment were defined as TSH <0.1 mIU/L or above 10 mIU/mL, respectively, in three consecutive measurements. Data were analyzed by Aalen-Johansen estimators and Cox proportional hazards models.Results: In total, 14 533 initiations of L-T4 were included in the study. The cumulative risk of being over- or undertreated was 4.7 and 7.4% after 10 years. The hazard of overtreatment was higher among women, younger adults, and with lower initial TSH levels. The hazard of overtreatment decreased over the time period from 2001 to 2012. Among overtreated individuals, the chance of returning to a normal TSH was about 55% after 10 years. In 18% of the cases, L-T4 therapy was initiated on TSH levels less than 5 mIU/L.Conclusion: Although a still decreasing threshold for initiating L-T4 therapy is known, the risk of overtreatment (and undertreatment) was low and lessened in the period 2001-2012 among Danish primary care patients. Nevertheless, as many as 18% were started on L-T4 with normal TSH levels.
AB - Objective: A decrease over time in thyroid stimulating hormone (TSH) levels when initiating levothyroxine (L-T4) therapy for hypothyroidism has been reported, where treatment most often is initiated with TSH levels below 10 mIU/L. The primary objective of this study was to investigate whether this lower TSH threshold resulted in an increased number of overtreated patients.Design and method: Retrospective cohort study comprising inhabitants in Copenhagen had TSH measurements requested by general practitioners which led to a new prescription of L-T4 between 2001 and 2012. Over- and under- treatment were defined as TSH <0.1 mIU/L or above 10 mIU/mL, respectively, in three consecutive measurements. Data were analyzed by Aalen-Johansen estimators and Cox proportional hazards models.Results: In total, 14 533 initiations of L-T4 were included in the study. The cumulative risk of being over- or undertreated was 4.7 and 7.4% after 10 years. The hazard of overtreatment was higher among women, younger adults, and with lower initial TSH levels. The hazard of overtreatment decreased over the time period from 2001 to 2012. Among overtreated individuals, the chance of returning to a normal TSH was about 55% after 10 years. In 18% of the cases, L-T4 therapy was initiated on TSH levels less than 5 mIU/L.Conclusion: Although a still decreasing threshold for initiating L-T4 therapy is known, the risk of overtreatment (and undertreatment) was low and lessened in the period 2001-2012 among Danish primary care patients. Nevertheless, as many as 18% were started on L-T4 with normal TSH levels.
KW - Adult
KW - Aged
KW - Cohort Studies
KW - Denmark/epidemiology
KW - Female
KW - Hormone Replacement Therapy
KW - Humans
KW - Hypothyroidism/drug therapy
KW - Male
KW - Medical Overuse/statistics & numerical data
KW - Middle Aged
KW - Primary Health Care/statistics & numerical data
KW - Retrospective Studies
KW - Risk Assessment
KW - Sensitivity and Specificity
KW - Thyrotropin/blood
KW - Thyroxine/administration & dosage
UR - http://www.scopus.com/inward/record.url?scp=85117941409&partnerID=8YFLogxK
U2 - 10.1530/EJE-21-0485
DO - 10.1530/EJE-21-0485
M3 - Journal article
C2 - 34478406
AN - SCOPUS:85117941409
SN - 0804-4643
VL - 185
SP - 673
EP - 679
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 5
ER -